Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Erdafitinib

FDA-approved product (tablet, oral), marketed as Balversa.

Registered studies
43
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Erdafitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bladder tumor
  • Cancer
  • Neoplasm
  • Urinary bladder cancer
  • Urothelial carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Erdafitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Erdafitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

    NCT03999515 · start 2020-04-27

    Registered record
    Registry ID
    NCT03999515
    Conditions
    Castration-Resistant Prostate Carcinoma; Double-Negative Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Abiraterone Acetate; Enzalutamide; Erdafitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-04-27
    Completion
    2021-06-06
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Double-Negative Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma +3 more
    InterventionAbiraterone Acetate; Enzalutamide; Erdafitinib
    PhasePhase 2
    Registry statusTerminated

  • A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants

    NCT04330248 · start 2020-03-31

    Registered record
    Registry ID
    NCT04330248
    Conditions
    Healthy
    Interventions
    Erdafitinib; Carbamazepine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-03-31
    Completion
    2022-06-14
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionErdafitinib; Carbamazepine
    PhasePhase 1
    Registry statusCompleted

  • A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

    NCT04172675 · start 2020-02-28

    Registered record
    Registry ID
    NCT04172675
    Conditions
    Urinary Bladder Neoplasms
    Interventions
    Erdafitinib; Investigator Choice (Gemcitabine); Investigator Choice (Mitomycin C)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-02-28
    Completion
    2025-02-27
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Bladder Neoplasms
    InterventionErdafitinib; Investigator Choice (Gemcitabine); Investigator Choice (Mitomycin C)
    PhasePhase 2
    Registry statusCompleted

  • A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

    NCT04083976 · start 2019-11-20

    Registered record
    Registry ID
    NCT04083976
    Conditions
    Advanced Solid Tumor
    Interventions
    Erdafitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-11-20
    Completion
    2026-02-28
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor
    InterventionErdafitinib
    PhasePhase 2
    Registry statusCompleted

  • A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

    NCT03955913 · start 2019-08-01

    Registered record
    Registry ID
    NCT03955913
    Conditions
    Urothelial Cancer; Receptors, Fibroblast Growth Factor
    Interventions
    Archival Tumor Tissue Sample
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-08-01
    Completion
    2022-09-19
    Enrolment
    3,679

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Cancer; Receptors, Fibroblast Growth Factor
    InterventionArchival Tumor Tissue Sample
    PhaseNot recorded
    Registry statusCompleted

  • Myeloma-Developing Regimens Using Genomics (MyDRUG)

    NCT03732703 · start 2019-04-01

    Registered record
    Registry ID
    NCT03732703
    Conditions
    Relapsed Refractory Multiple Myeloma
    Interventions
    Abemaciclib, dexamethasone, ixazomib, pomalidomide; Enasidenib, dexamethasone, ixazomib, pomalidomide; Cobimetinib, dexamethasone, ixazomib, pomalidomide; Erdafitinib, dexamethasone, ixazomib, pomalidomide; Venetoclax, dexamethasone, ixazomib, pomalidomide; Daratumumab, dexamethasone, ixazomib, pomalidomide; Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide; Selinexor, dexamethasone, ixazomib, pomalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-04-01
    Completion
    2024-12-31
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Refractory Multiple Myeloma
    InterventionAbemaciclib, dexamethasone, ixazomib, pomalidomide; Enasidenib, dexamethasone, ixazomib, pomalidomide; Cobimetinib, dexamethasone, ixazomib, pomalidomide; Erdafitinib, dexamethasone, ixazomib, pomalidomide +4 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • FGFR Inhibitor in FGFR Dysregulated Cancer

    NCT03827850 · start 2019-03-25

    Registered record
    Registry ID
    NCT03827850
    Conditions
    Lung Cancer; NSCLC; Pulmonary Neoplasm; Squamous Cell Lung Cancer; NSCLC Stage IV
    Interventions
    ERDAFITINIB
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-03-25
    Completion
    2022-10-14
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; NSCLC; Pulmonary Neoplasm; Squamous Cell Lung Cancer +1 more
    InterventionERDAFITINIB
    PhasePhase 2
    Registry statusTerminated

  • A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

    NCT03587363 · start 2018-12-06

    Registered record
    Registry ID
    NCT03587363
    Conditions
    Hepatic Impairment
    Interventions
    Erdafitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-12-06
    Completion
    2020-12-22
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionErdafitinib
    PhasePhase 1
    Registry statusTerminated

  • A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

    NCT03547037 · start 2018-08-31

    Registered record
    Registry ID
    NCT03547037
    Conditions
    Neoplasm
    Interventions
    JNJ-63723283; Erdafitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-08-31
    Completion
    2022-07-04
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasm
    InterventionJNJ-63723283; Erdafitinib
    PhasePhase 1
    Registry statusCompleted

  • Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

    NCT06308822 · start 2018-08-20

    Registered record
    Registry ID
    NCT06308822
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Computed Tomography; Erdafitinib; Magnetic Resonance Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-08-20
    Completion
    2027-01-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm +1 more
    InterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Erdafitinib +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

    NCT06351371 · start 2018-07-03

    Registered record
    Registry ID
    NCT06351371
    Conditions
    Malignant Solid Neoplasm
    Interventions
    Biopsy Procedure; Biospecimen Collection; Computed Tomography; Erdafitinib; Magnetic Resonance Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-07-03
    Completion
    2027-01-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Solid Neoplasm
    InterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Erdafitinib +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

    NCT03210714 · start 2018-06-05

    Registered record
    Registry ID
    NCT03210714
    Conditions
    Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Osteosarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Refractory Childhood Malignant Germ Cell Tumor; Refractory Childhood Osteosarcoma; Refractory Childhood Rhabdomyosarcoma; Refractory Childhood Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Re
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan; Computed Tomography; Erdafitinib; Laboratory Biomarker Analysis; Magnetic Resonance Imaging; Pharmacological Study; Positron Emission Tomography; Radionuclide Imaging; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-06-05
    Completion
    2026-12-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma +23 more
    InterventionBiospecimen Collection; Bone Marrow Aspiration and Biopsy; Bone Scan; Computed Tomography +7 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

    NCT03473743 · start 2018-04-05

    Registered record
    Registry ID
    NCT03473743
    Conditions
    Urothelial Carcinoma
    Interventions
    Erdafitinib; Cetrelimab; Cisplatin; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2018-04-05
    Completion
    2026-12-31
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Carcinoma
    InterventionErdafitinib; Cetrelimab; Cisplatin; Carboplatin
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

    NCT03390504 · start 2018-03-23

    Registered record
    Registry ID
    NCT03390504
    Conditions
    Urothelial Cancer
    Interventions
    Erdafitinib; Vinflunine; Docetaxel; Pembrolizumab; Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2018-03-23
    Completion
    2027-12-31
    Enrolment
    629

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Cancer
    InterventionErdafitinib; Vinflunine; Docetaxel; Pembrolizumab +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

    NCT03238196 · start 2017-08-18

    Registered record
    Registry ID
    NCT03238196
    Conditions
    Metastatic Breast Cancer
    Interventions
    Erdafitinib; Palbociclib; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-08-18
    Completion
    2024-03-20
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionErdafitinib; Palbociclib; Fulvestrant
    PhasePhase 1
    Registry statusCompleted